BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21135144)

  • 21. Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.
    Batra J; Lose F; O'Mara T; Marquart L; Stephens C; Alexander K; Srinivasan S; Eeles RA; Easton DF; Al Olama AA; Kote-Jarai Z; Guy M; Muir K; Lophatananon A; Rahman AA; Neal DE; Hamdy FC; Donovan JL; Chambers S; Gardiner RA; Aitken J; Yaxley J; Kedda MA; Clements JA; Spurdle AB
    PLoS One; 2011; 6(11):e26527. PubMed ID: 22132073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes.
    Enjuanes A; Benavente Y; Hernández-Rodríguez J; Queralt C; Yagüe J; Jares P; de Sanjosé S; Campo E; Cid MC
    Rheumatology (Oxford); 2012 May; 51(5):841-51. PubMed ID: 22258388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy.
    Chang CF; Pao JB; Yu CC; Huang CY; Huang SP; Yang YP; Huang CN; Chang TY; You BJ; Lee HZ; Hour TC; Bao BY
    Ann Surg Oncol; 2013 Jul; 20(7):2446-52. PubMed ID: 23397154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer.
    Deng Y; Xie K; Logothetis CJ; Thompson TC; Kim J; Huang M; Chang DW; Gu J; Wu X; Ye Y
    Carcinogenesis; 2020 Aug; 41(8):1057-1064. PubMed ID: 32215555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance.
    Pham MH; Bonello GB; Castiblanco J; Le T; Sigala J; He W; Mummidi S
    PLoS One; 2012; 7(11):e49498. PubMed ID: 23166687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
    Xie W; Yang M; Chan J; Sun T; Mucci LA; Penney KL; Lee GS; Kantoff PW
    Prostate; 2016 May; 76(7):691-9. PubMed ID: 26847995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.
    Chen YC; Giovannucci E; Kraft P; J Hunter D
    Carcinogenesis; 2008 May; 29(5):999-1004. PubMed ID: 18375959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer.
    Sunakawa Y; Stremitzer S; Cao S; Zhang W; Yang D; Wakatsuki T; Ning Y; Yamauchi S; Stintzing S; Sebio A; El-Khoueiry R; Matsusaka S; Parekh A; Barzi A; Azuma M; Watanabe M; Koizumi W; Lenz HJ
    Ann Oncol; 2015 Feb; 26(2):332-9. PubMed ID: 25411415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Prostaglandin-endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy.
    Lee CH; Pao JB; Lu TL; Lee HZ; Lee YC; Liu CC; Huang CY; Lin VC; Yu CC; Yin HL; Huang SP; Bao BY
    Int J Med Sci; 2016; 13(9):696-700. PubMed ID: 27647999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphism rs3760396 of the chemokine (C-C motif) ligand 2 gene (CCL2) associated with the susceptibility of lung cancer in a pathological subtype-specific manner in Han-ancestry Chinese: a case control study.
    Li X; Lin F; Zhou H
    BMC Cancer; 2016 May; 16():298. PubMed ID: 27145753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
    Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
    Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer susceptibility variants confer increased risk of disease progression.
    Cheng I; Plummer SJ; Neslund-Dudas C; Klein EA; Casey G; Rybicki BA; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2124-32. PubMed ID: 20651075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer.
    Kucukgergin C; Isman FK; Cakmakoglu B; Sanli O; Seckin S
    DNA Cell Biol; 2012 Aug; 31(8):1418-24. PubMed ID: 22612293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variation in the HSD17B1 gene and risk of prostate cancer.
    Kraft P; Pharoah P; Chanock SJ; Albanes D; Kolonel LN; Hayes RB; Altshuler D; Andriole G; Berg C; Boeing H; Burtt NP; Bueno-de-Mesquita B; Calle EE; Cann H; Canzian F; Chen YC; Crawford DE; Dunning AM; Feigelson HS; Freedman ML; Gaziano JM; Giovannucci E; Gonzalez CA; Haiman CA; Hallmans G; Henderson BE; Hirschhorn JN; Hunter DJ; Kaaks R; Key T; Le Marchand L; Ma J; Overvad K; Palli D; Pike MC; Riboli E; Rodriguez C; Setiawan WV; Stampfer MJ; Stram DO; Thomas G; Thun MJ; Travis R; Trichopoulou A; Virtamo J; Wacholder S
    PLoS Genet; 2005 Nov; 1(5):e68. PubMed ID: 16311626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer.
    Binder M; Shui IM; Wilson KM; Penney KL; ; Mucci LA; Kibel AS
    Cancer Causes Control; 2015 Dec; 26(12):1751-9. PubMed ID: 26407952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCL2 -2518 A/G single nucleotide polymorphism as a risk factor for breast cancer.
    Kruszyna L; Lianeri M; Rubis B; Knuła H; Rybczyńska M; Grodecka-Gazdecka S; Jagodziński PP
    Mol Biol Rep; 2011 Feb; 38(2):1263-7. PubMed ID: 20563852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease.
    Bao BY; Pao JB; Lin VC; Huang CN; Chang TY; Lan YH; Lu TL; Lee HZ; Chen LM; Ting WC; Hsieh CJ; Huang SP
    Clin Chim Acta; 2010 Sep; 411(17-18):1232-7. PubMed ID: 20450899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.